Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Clinical management, consisting of regular monitoring, and for a minority of people pharmaceutical treatment, reduces hepatitis B disease progression.
Of all people with hepatitis B in Australia, only 13 per cent are clinically managed and of the 5 per cent that do receive pharmaceutical treatment, 20 per cent do not regularly take their medication.
A major gap in the public health response to hepatitis B is to identify the reasons for the reported ‘non-compliance’ of people with hepatitis B to the current model of care or identifying the elements of an effective clinical guideline and future model of care.
2020 – 2021
For any general enquiries relating to this project, please contact:
Senior Research Officer
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
